OncoSTING Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.5M

  • Investors
  • 4

OncoSTING General Information

Description

Developer of a biopharma therapy designed to cure bladder cancer. The company's therapy combines the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.

Contact Information

Website
www.oncosting.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 17 South Chester Street
  • Baltimore, MD 21231
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 17 South Chester Street
  • Baltimore, MD 21231
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSTING Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jun-2022 $2.5M 00000 Completed Generating Revenue
4. Grant 08-Jul-2019 00000 00000 Completed Generating Revenue
3. Early Stage VC 02-Jul-2019 00000 00000 Completed Generating Revenue
2. Accelerator/Incubator 28-Jun-2019 Completed Generating Revenue
1. Grant 23-Feb-2018 Completed Generating Revenue
To view OncoSTING’s complete valuation and funding history, request access »

OncoSTING Executive Team (4)

Name Title Board Seat
Trinity Bivalacqua Ph.D Co-Founder
Todd Wallach Chief Executive Officer
William Bishai Ph.D Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

OncoSTING Board Members (1)

Name Representing Role Since
Ambaw Bellete Self Chairman 000 0000
To view OncoSTING’s complete board members history, request access »

OncoSTING Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoSTING Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
Johns Hopkins University Endowment Limited Partner 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view OncoSTING’s complete investors history, request access »

Ready to get started?

Request a free trial

OncoSTING FAQs

  • When was OncoSTING founded?

    OncoSTING was founded in 2018.

  • Who is the founder of OncoSTING?

    Trinity Bivalacqua Ph.D and William Bishai Ph.D are the founders of OncoSTING.

  • Who is the CEO of OncoSTING?

    Todd Wallach is the CEO of OncoSTING.

  • Where is OncoSTING headquartered?

    OncoSTING is headquartered in Baltimore, MD.

  • What is the size of OncoSTING?

    OncoSTING has 3 total employees.

  • What industry is OncoSTING in?

    OncoSTING’s primary industry is Biotechnology.

  • Is OncoSTING a private or public company?

    OncoSTING is a Private company.

  • What is OncoSTING’s current revenue?

    The current revenue for OncoSTING is 00000.

  • How much funding has OncoSTING raised over time?

    OncoSTING has raised $150K.

  • Who are OncoSTING’s investors?

    National Institutes of Health, National Science Foundation, Johns Hopkins University Endowment, and TEDCO have invested in OncoSTING.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »